Audentes Therapeutics (NASDAQ:BOLD) Downgraded to Market Perform at BMO Capital Markets

Share on StockTwits

BMO Capital Markets lowered shares of Audentes Therapeutics (NASDAQ:BOLD) from an outperform rating to a market perform rating in a research note released on Tuesday morning, Benzinga reports. They currently have $60.00 target price on the biotechnology company’s stock, up from their previous target price of $47.00.

BOLD has been the subject of a number of other reports. BidaskClub downgraded Audentes Therapeutics from a sell rating to a strong sell rating in a report on Friday, November 8th. Evercore ISI raised Audentes Therapeutics from an in-line rating to an outperform rating in a research note on Wednesday, November 27th. HC Wainwright reissued a buy rating and issued a $48.00 price objective on shares of Audentes Therapeutics in a research note on Friday, November 8th. Robert W. Baird upgraded Audentes Therapeutics from an underperform rating to a neutral rating in a research report on Tuesday. Finally, ValuEngine cut Audentes Therapeutics from a buy rating to a hold rating in a research note on Friday, November 8th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and six have given a buy rating to the company’s stock. Audentes Therapeutics currently has a consensus rating of Hold and an average target price of $44.50.

NASDAQ:BOLD opened at $58.93 on Tuesday. Audentes Therapeutics has a 52 week low of $17.95 and a 52 week high of $59.01. The firm’s fifty day moving average is $28.32 and its 200-day moving average is $33.21. The firm has a market cap of $1.33 billion, a P/E ratio of -17.33 and a beta of 1.77.

Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($1.00) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.07. During the same quarter in the prior year, the company posted ($0.97) EPS. As a group, equities analysts expect that Audentes Therapeutics will post -4.13 EPS for the current year.

In related news, Director Louis G. Lange sold 10,000 shares of the business’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $32.16, for a total value of $321,600.00. Following the completion of the sale, the director now directly owns 276,044 shares of the company’s stock, valued at approximately $8,877,575.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Matthew R. Patterson sold 14,426 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $30.00, for a total value of $432,780.00. Following the transaction, the chief executive officer now directly owns 127,820 shares in the company, valued at $3,834,600. The disclosure for this sale can be found here. 5.30% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in BOLD. Meeder Asset Management Inc. increased its holdings in shares of Audentes Therapeutics by 578.5% during the second quarter. Meeder Asset Management Inc. now owns 726 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 619 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Audentes Therapeutics by 50.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,990 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 1,005 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Audentes Therapeutics by 1.8% in the 3rd quarter. Rhumbline Advisers now owns 61,051 shares of the biotechnology company’s stock worth $1,715,000 after purchasing an additional 1,070 shares in the last quarter. Aperio Group LLC bought a new position in shares of Audentes Therapeutics in the 2nd quarter worth $46,000. Finally, Swiss National Bank grew its position in Audentes Therapeutics by 2.1% in the 2nd quarter. Swiss National Bank now owns 67,500 shares of the biotechnology company’s stock valued at $2,556,000 after purchasing an additional 1,400 shares during the period. 98.08% of the stock is owned by hedge funds and other institutional investors.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

See Also: What is total return in investing?

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.